Intuitive Surgical, Inc. (ISRG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Intuitive Surgical, Inc. (ISRG) Healthcare & Pipeline Overview

Intuitive Surgical, Inc. is a leader in minimally invasive surgical technology, offering advanced robotic systems and instrumentation that improve surgical outcomes and operational efficiencies for healthcare providers globally.

What Is the Investment Thesis for ISRG?

Intuitive Surgical, Inc. demonstrates robust financial health with a market capitalization of $138B and a profit margin of 28.2%. The company's growth is driven by increasing adoption of its da Vinci Surgical System, which is expected to see a compound annual growth rate (CAGR) of 10% through 2028 as more healthcare providers recognize the benefits of minimally invasive procedures. Additionally, the expansion of the Ion endoluminal system into new markets presents significant revenue potential. While the company faces ongoing risks such as regulatory scrutiny and competition from emerging technologies, its established market position and continuous innovation provide a strong foundation for sustained growth. Furthermore, the absence of dividends indicates a focus on reinvestment into R&D and expansion, aligning with long-term value creation strategies.

Based on FMP financials and quantitative analysis

ISRG Key Highlights

Market capitalization of $138B reflects strong investor confidence and growth potential.

• Profit margin of 28.2% showcases operational efficiency and effective cost management.
• Gross margin of 66.3% significantly exceeds industry averages, indicating strong pricing power.
• P/E ratio of 46.3 suggests high growth expectations from the market.
• Beta of 1.68 indicates higher volatility compared to the overall market, reflecting investor sentiment.

Who Are ISRG's Competitors?

ISRG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ISRG's Key Strengths?

Leading position in the minimally invasive surgical market.

• High profit margins indicating operational efficiency.
• Strong brand loyalty among healthcare providers and surgeons.
• Robust pipeline of innovative products and technologies.

What Are ISRG's Weaknesses?

High reliance on the da Vinci Surgical System for revenue.

• No dividend payments, which may deter income-focused investors.
• Potential for high costs associated with R&D and regulatory compliance.
• Vulnerability to competition from emerging technologies and new entrants.

What Could Drive ISRG Stock Higher?

ISRG catalyst: Expansion of the da Vinci Surgical System into new surgical specialties expected to drive sales growth.

• Continued adoption of the Ion endoluminal system in diagnostic procedures enhancing revenue streams.
• Launch of new training programs aimed at increasing the utilization of surgical systems among healthcare providers.
• Strategic partnerships with healthcare institutions to enhance service offerings and market reach.

What Are the Key Risks for ISRG?

Rich valuation — a P/E of 46.3 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $7.9M recently.
• Regulatory changes that could impact product approval processes and market access.
• Competition from emerging surgical technologies that may challenge market share.
• Economic fluctuations affecting hospital budgets and investment in surgical technologies.
• Dependence on the da Vinci Surgical System for a significant portion of revenue, posing risks if market dynamics change.

What Are the Growth Opportunities for ISRG?

• Expansion of the da Vinci Surgical System: The global surgical robotics market is expected to grow from $4.5 billion in 2021 to $12.6 billion by 2028, presenting a significant opportunity for Intuitive Surgical to expand its market share through increased adoption of its da Vinci system across various surgical specialties.
• Geographic Market Penetration: Intuitive Surgical is focusing on expanding its presence in emerging markets, particularly in Asia-Pacific, where healthcare infrastructure is rapidly developing. This region is projected to see a CAGR of 9% in surgical procedures, providing a fertile ground for growth.
• Introduction of New Products: The launch of the Ion endoluminal system represents a strategic move to diversify the product portfolio. The global endoscopy market is expected to reach $45 billion by 2027, driven by increasing demand for minimally invasive diagnostic procedures, which can enhance revenue streams for Intuitive Surgical.
• Partnerships and Collaborations: Intuitive Surgical is actively seeking partnerships with healthcare providers and technology firms to enhance its service offerings. Collaborations in telehealth and digital solutions can improve patient outcomes and operational efficiencies, further solidifying its market position.
• Investment in R&D: Continuous investment in research and development is crucial for maintaining a competitive edge. Intuitive Surgical's commitment to innovation is expected to yield new technologies and enhancements to existing products, driving future growth and customer loyalty.

What Threats Does ISRG Face?

• Intense competition from established and new players in the market.
• Regulatory challenges and potential changes in healthcare policies.
• Economic downturns affecting hospital budgets and capital expenditures.
• Technological advancements by competitors that may outpace Intuitive Surgical's innovations.

What Are ISRG's Competitive Advantages?

• Strong brand recognition and reputation for quality in surgical technology.
• Proprietary technology and patents protecting key innovations.
• Established relationships with healthcare providers and institutions globally.
• Comprehensive training and support services that enhance customer loyalty.

What Does ISRG Do?

Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical, Inc. has emerged as a pioneer in the field of minimally invasive surgery. The company is best known for its flagship product, the da Vinci Surgical System, which revolutionizes surgical procedures by allowing surgeons to perform complex operations with enhanced precision through small incisions. This system integrates advanced robotic technology with high-definition 3D visualization, enabling a level of control and dexterity that traditional surgical methods cannot match. In addition to the da Vinci system, Intuitive Surgical has expanded its product offerings to include the Ion endoluminal system, which facilitates minimally invasive biopsies in the lung, thereby broadening its reach into diagnostic procedures. The company also provides a comprehensive suite of surgical instruments, including stapling and energy devices, along with progressive learning pathways and extensive support services for healthcare providers. Intuitive Surgical's commitment to innovation and quality has positioned it as a trusted partner for hospitals and surgical centers worldwide, enhancing the quality of care while reducing recovery times for patients. With a workforce of over 15,600 employees, the company continues to invest in research and development to maintain its competitive edge in the evolving healthcare landscape.

What Products and Services Does ISRG Offer?

• Develop and manufacture the da Vinci Surgical System for minimally invasive surgeries.
• Provide the Ion endoluminal system for lung biopsies and diagnostic procedures.
• Offer a comprehensive suite of surgical instruments, including stapling and energy devices.
• Deliver progressive learning pathways to support healthcare providers in using their technology.
• Provide extensive customer support services, including installation, repair, and maintenance.
• Integrate digital capabilities to enhance operational performance and insights for hospitals.

How Does ISRG Make Money?

• Generate revenue primarily through the sale of surgical systems and instruments.
• Offer ongoing service contracts and support for installed systems, creating a recurring revenue stream.
• Leverage training and education programs to enhance customer engagement and product utilization.
• Expand product offerings to include diagnostic tools and digital solutions, diversifying revenue sources.

What Industry Does ISRG Operate In?

The medical instruments and supplies industry is experiencing rapid growth, driven by technological advancements and an increasing demand for minimally invasive surgical procedures. The global market for surgical instruments is projected to reach $50 billion by 2028, with a CAGR of approximately 7%. Intuitive Surgical, Inc. occupies a leading position within this market, primarily due to its innovative da Vinci Surgical System, which has set a benchmark for surgical precision and efficiency. The competitive landscape includes notable players such as Becton, Dickinson and Company (BDX), ResMed Inc. (RMD), Hologic, Inc. (HOLX), The Cooper Companies, Inc. (COO), and Baxter International Inc. (BAX), all of which are vying for market share in a rapidly evolving sector.

Who Are ISRG's Key Customers?

• Hospitals and surgical centers seeking advanced surgical technologies.
• Healthcare providers looking for minimally invasive surgical solutions.
• Surgeons specializing in various fields, including urology, gynecology, and thoracic surgery.
• Diagnostic facilities aiming to enhance their biopsy capabilities with innovative tools.

Intuitive Surgical, Inc. Financial Trajectory

Intuitive Surgical, Inc. (ISRG) reported $2.89B in revenue for Q2 2026, reflecting 4.4% growth compared to the prior quarter. The company recorded net income of $818.1M, with diluted EPS of $2.35. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ISRG averaged $2.20 in diluted EPS.

Company Profile

Intuitive Surgical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO David J. Rosa. ISRG has traded publicly since 2000.

How Intuitive Surgical, Inc. Is Valued

Intuitive Surgical, Inc. carries a market capitalization of $138B, placing it in the large-cap category. Relative to its peer group, ISRG's quantitative score of 94/100 is above the peer average of 70/100.

Return on equity for Intuitive Surgical, Inc. stands at 17.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.8%, showing how much profit it generates from its asset base. ISRG trades at a trailing price-to-earnings ratio of 46.34, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

Intuitive Surgical, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 34.17 places it in the safe zone, indicating low near-term bankruptcy risk.

Intuitive Surgical, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 14.1% above estimates on average.

Wall Street analysts project Intuitive Surgical, Inc. revenue of about $11.76B for fiscal 2026, with EPS near $10.80. The estimate reflects 25 contributing analysts.

Over the past six months, Intuitive Surgical, Inc. insiders filed 30 SEC Form 4 transactions — 27 sales and 3 purchases. On net that is roughly 19K shares disposed (about $7.9M), a signal worth weighing alongside the fundamentals.

ISRG Financials

ISRG Latest News

ISRG Analyst Consensus

ISRG MoonshotScore

Latest Intuitive Surgical, Inc. Analysis

Related Investment Themes

Intuitive Surgical, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources